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Background: We examined the prognostic value of a panel of biomarkers in patients
with squamous cell carcinoma of the head and neck (SCCHN) who were human
immunodeficiency virus (HIV) positive (HIV-positive head and neck cancer) and
HIV negative (HIV-negative head and neck cancer).
Methods: Tissue microarrays (TMAs) were constructed using tumors from 41 disease
site-matched and age-matched HIV-positive head and neck cancer cases and 44 HIV-
negative head and neck cancer controls. Expression of tumor biomarkers was assessed
by immunohistochemistry (IHC) and correlations examined with clinical variables.
Results: Expression levels of the studied oncogenic and inflammatory tumor bio-
markers were not differentially regulated by HIV status. Among patients with HIV-
positive head and neck cancer, laryngeal disease site (P 5 .003) and Clavien-Dindo
classification IV (CD4) counts <200 cells/lL (P 5 .01) were associated with poor
prognosis. Multivariate analysis showed that p16 positivity was associated with
improved overall survival (OS; P < .001) whereas increased expression of transform-
ing growth factor-beta (TGF-b) was associated with poor clinical outcome (P 5 .001).
Conclusion: Disease site has significant effect on the expression of biomarkers.
Expression of tumor TGF-b could be a valuable addition to the conventional risk
stratification equation for improving head and neck cancer disease management
strategies.
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1 | INTRODUCTION
The continued improvement and availability of highly
active antiretroviral therapy (HAART) has dramatically
prolonged survival in people living with human immuno-
deficiency virus (HIV) infection and AIDS. Although the
incidence of AIDS-defining malignancies has declined in
the post-HAART era, large epidemiological studies pro-
vide emerging evidence of increased risk of non-AIDS-
defining cancers (non-AIDS-defining malignancies) over
the past decade.1,2 The incidence of squamous cell carci-
noma of the head and neck (SCCHN) is 4-fold higher in
patients infected with HIV than in the general popula-
tion.3,4 Smoking and alcohol consumption are known risk
factors for the development of head and neck cancer5,6 in
both patients who are HIV-positive and HIV-negative.7 In
addition, patients who are infected with HIV are suscepti-
ble to infection by oncogenic viruses, which may contrib-
ute to the higher rates of SCCHN. The risk of human
papillomavirus (HPV)-associated SCCHN was found to be
elevated among persons with AIDS and increased with
increasing degrees of immunosuppression.8,9
Non-AIDS-defining malignancies, including oral cavity
and pharyngeal cancer, are often associated with younger
age at diagnosis of cancer and more aggressive and advanced
stages of disease in the HIV-infected patient population than
in the HIV-negative population.10–12 Advanced cirrhosis and
poorer outcome has been reported among patients infected
with HIV with hepatocellular carcinoma13; a higher risk of
local recurrence and metastasis were also noted in patients
infected with HIV with skin squamous cell carcinoma.14
Poor survival in patients infected with HIV SCCHN is asso-
ciated with low CD4 counts, a laryngeal/hypopharyngeal pri-
mary site and current tobacco use.15 Thus, concerns over
optimal treatment strategies and disease management arise
when treating patients infected with HIV with SCCHN, espe-
cially smokers and alcohol users who have higher burden of
comorbidity and possible coinfection with HPV.16 The iden-
tification of prognostic factors in patients infected with HIV
with SCCHN would be pivotal to the development of effec-
tive cancer prevention, surveillance, and treatment strategies.
Hence, in this study, we examined protein expression of
a panel of candidate prognostic biomarkers (nuclear factor-
kappa b [NF-jb], phosphorylated protein kinase B (pAKT)
S473, pSTAT3Y705, B-cell lymphoma 2 (Bcl-2), transform-
ing growth factor-beta [TGF-b], interleukin [IL]-6, and vas-
cular endothelial growth factor A [VEGF-A]), known to be
associated with oncogenic activities, involved in the complex
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host-tumor interaction, or to function as inflammatory
mediators,17–21 acting either independently or in concerted
fashion. Chronic inflammation affects all stages of cancer
development22 and signal transducer and activator of tran-
scription 3 (STAT3), NF-jB, and IL-6 are key players in
mediating the signaling pathways involved in inflammation-
induced carcinogenesis, with the tissue microenvironment
being the focal point of interaction between the tumor and
host immune system.23 Lung tumor growth in immunodefi-
cient mice promoted by inflammation has been shown to be
mediated by IL-6 through the STAT3/mitogen-activated pro-
tein kinase and NF-jB pathways, suggesting a strong causal
link among immunodeficiency, inflammation, and cancer
orchestrated by the STAT3 and NF-jB pathways.24 Further-
more, immunosuppression can be worsened by proinflamma-
tory factors induced by cigarette smoking25,26 in which
process of the phosphotidylinositol-3-kinase/protein kinase B
(AKT)/NF-jB pathway has been frequently implicated.27
Like IL-6, TGF-b, an inflammatory cytokine and potent
immune suppressor produced by cancer cells, myeloid cells,
and T lymphocytes play a dual role in tumor suppression and
promotion.20 The Cancer Genome Atlas investigations in
SCCHN have revealed that mutation profile and rates vary
substantially by HPV infection, anatomic subsite, and smok-
ing history,28 which makes the identification of prognostic
tumor biomarkers daunting. Thus, we conducted a retrospec-
tive study using tissue microarray (TMA) with tumor tissues
derived from disease site-matched and age-matched patients
with SCCHN who were HIV infected (HIV-positive head and
neck cancer) and non-HIV-infected control patients (HIV-
negative head and neck cancer). These rare specimens were
acquired through the concerted effort of 5 Head and Neck
Specialized Program of Research Excellence (HN-SPORE)
centers. The purpose of this exploratory study was to examine
the prognostic potential of candidate tumor biomarkers.
2 | PATIENTS AND METHODS
2.1 | Patients and tissue microarray
construction
Patients were identified from 1 of 5 US tertiary care referral
centers (Emory University, Johns Hopkins University, MD
Anderson Cancer Center, University of Michigan, and Uni-
versity of Pittsburgh). The patients with HIV-positive head
and neck cancer were diagnosed between 1991 and 2011;
patients with HIV-negative head and neck cancer were diag-
nosed between 1996 and 2010. The study was approved by
the institutional review boards of all participating institutions
and was conducted using anonymized specimens.
The TMA was designed using tumor tissues derived from
HIV-positive head and neck cancer cases and HIV-negative
head and neck cancer controls with sufficient viable tumor
tissues that allowed anatomic subsite and age matching.
Deidentified information, including demographic and clinical
information, documentation of HIV infection, cancer diagnosis,
behavior information, CD4 counts, viral load, and HAART use
at the time of cancer diagnosis were submitted to the study data
center as previously described.15 Specimens were collected per
recommended guidelines29,30 according to a well-defined proto-
col via collaboration of the head and neck cancer SPORE HIV
consortium, and the TMA was centrally constructed and distrib-
uted by the University of Michigan. For each biomarker, 2
TMA slides (4-lm thickness) and 1 hematoxylin-eosin stained
slide were obtained. Supporting Information Table S1 shows
the number of cases used for each biomarker staining and the
number of cases with clinical information.
2.2 | Immunohistochemistry
Immunohistochemistry (IHC) was performed with validated
antibodies: pATKS473 (1:100, clone EP2109Y; Epitomics,
Burlingame, CA), Bcl-2 (1:50, clone 100; CalBiochem, San
Diego, CA), IL-6 (1:500; AbCam, Cambridge, UK), NF-
jBp65 (1:200, C-20; Santa Cruz Biotechnology, Dallas, TX),
pSTAT3Y705 (1:25, clone D3A7; Santa Cruz Biotechnol-
ogy), TGF-b (1:50; Santa Cruz Biotechnology), and VEGF-
A (1:100, clone A-20; Santa Cruz Biotechnology). Primary
antibody incubation was carried out overnight at 48C fol-
lowed by secondary antibody incubation at room temperature.
Finally, slides were incubated with 3,30-diaminobenzidine to
visualize staining and counterstained with hematoxylin. A
nonmalignant non-head and neck cancer tissue sample was
included as a negative control. Tumors were tested for p16
expression as a marker of oncogenic HPV by IHC using the
CINtec p16 Histology kit and protocol (MTM Laboratories,
Westborough, MA). The IHC scores 12 were considered
p16 positive.15 The results of p16 staining were provided by
investigators at the University of Michigan. The whole cell
staining of all other biomarkers was assessed regardless of
nuclear and/or cytoplasmic localization. Scoring was
described previously15; briefly, intensity of tumor cells stain-
ing: 1 5 no staining, 2 5 low, 3 5 moderate, and 4 5 high;
proportion of tumor cells staining: 1: <5%, 2: 5%-20%, 3:
21%-50%, and 4: 51%-100%. The IHC scores (proportion
times intensity) from each tissue core section were averaged
for each patient. All specimens were scored by a board-
certified pathologist (G.S.) blinded to tumor categories.
Tumor HPV DNA testing was conducted using PCR
MassArray by investigators at the University of Michigan, as
previously described,15 all specimens with identified high-
risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66, 68, and 73) were scored as HPV-positive.
2.3 | Statistical analysis
Comparison between HIV-positive head and neck cancer cases
and HIV-negative head and neck cancer control patients’
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characteristics and the correlation of IHC scores with clinical
covariables were conducted using the t test or Wilcoxon rank-
sum test in which assumption of normal distribution was vio-
lated for numerical variables, and the chi-square test or Fisher’s
exact test for categorical variables. A logistic regression model
was used to examine the adjusted association of each variable
with HIV status after adjusting for other factors. Pairwise corre-
lations between the 7 biomarkers were examined with Pearson
or Spearman correlation coefficients. Univariate association of
each biomarker with covariates was examined with the t test or
Wilcoxon rank-sum test for categorical covariates, and Pearson
correlation or Spearman correlation coefficient for numerical
covariates, where appropriate.
Survival estimates were calculated for dichotomized bio-
markers, binary prognostic factors, HIV status, and other cate-
gorical variables with the Kaplan-Meier method and compared
between 2 stratified groups using the log-rank test.31 Univariate
and multivariable survival analyses were carried out using the
Cox proportional hazards model.32 The proportional hazards
assumption was also examined with scaled Schoenfeld resid-
uals.33 To avoid choosing arbitrary cutoff points in the levels
of biomarker expression, continuous variables were used in the
model. Multivariable survival analysis was carried out by
entering all variables in a Cox proportional hazard model and
using a backward variable selection method with an alpha level
of removal of 0.15, whereas the HIV variable was arbitrarily
kept in the model. The HAART use at diagnosis and CD4
counts at cancer diagnosis were not included in the model as
they were available only for patients with HIV-positive disease.
January first of the year was used in which only the year of
diagnosis or year of death/last contact was available. All analy-
ses were performed using SAS 9.3 (SAS Institute, Cary, NC)
and R package version 3.3.2 (The R Foundation for Statistical
Computing) with 2-sided tests and a significance level of 0.05.
3 | RESULTS
3.1 | Patient characteristics
Forty-one cases with sufficient tumor tissues were identified
from the original total of 71 patients with HIV-positive head
and neck cancer who had HIV-related clinical information;
44 cases with sufficient anatomic subsite-matched and age-
matched tumor tissues were identified from the 47 HIV-
negative head and neck cancer control patients. Patient char-
acteristics are shown in Table 1. We initially examined
whether the subset used for the TMA study reflected the
characteristics of the original HIV-positive head and neck
cancer cohort15: the majority of the current subset were men
(92.7%) versus 90.0% in the original cohort, 65.9% were on
HAART at the time of cancer diagnosis (vs 80.3%), 19.5%
had CD4 counts below 200 cells/lL (vs 26.8%), 65.9% were
current alcohol users (vs 55.3%), and 19.5% were HPV-
positive (vs 27.9% in the original cohort).
Eight of 41 HIV-positive head and neck cancer cases
were HPV-positive as determined by HPV DNA testing
(19.5%; 1 with HPV18 and 7 with HPV16); 5 of the orophar-
ynx, 1 of the oral cavity, 1 of the larynx, and 1 of the parotid
gland. Eight of 44 cases in the HIV-negative head and neck
cancer group had HPV-positive disease (18%; 1 with HPV33
and 7 with HPV16); 5 were oropharyngeal, 2 were oral cav-
ity, and 1 was laryngeal. Patients with HPV-positive disease
were younger (48.3 6 9.1) than patients who were HPV-
negative (52.8 6 10.3), although the difference was not sig-
nificant (P 5 .11). The HIV-positive head and neck cancer
group included 1 case of a parotid tumor, and the HIV-
negative head and neck cancer group included 1 case of con-
junctiva and 1 case of esophageal cancer.
Thirty-two of 41 patients (78.0%) with HIV-positive
head and neck cancer had CD4 levels examined at the time
of cancer diagnosis, 24 of these patients (75%) had CD4
counts 200 cells/lL. African Americans accounted for
71.4% of patients with low CD4 (<200 cells/lL). Within the
HIV-positive group, 36 of 41 patients (87.8%) had HAART
information available; 27 of these patients (75%) had taken
HAART at the time of cancer diagnosis and 82.6% of the
patients receiving HAART had high CD4 counts (200
cells/lL) compared with 57.1% of patients not taking
HAART (P 5 .30; data not shown). The CD4 count was not
correlated with stage at presentation, but interestingly, was
significantly associated with disease site (P 5 .001); of the 8
patients with low CD4 counts (<200 cells/lL), 4 had laryn-
geal cancer (50%) compared with 13% (3/24) in patients with
higher CD4 counts (200 cells/lL; data not shown).
When the HIV-positive head and neck cancer group was
stratified by HPV status, patients with HPV-positive disease
had significantly higher median CD4 counts (n 5 8; median
567; range 209-872) than HPV-negative patients (n 5 26;
median 232; range 5-700; P 5 .04). Expression of bio-
markers did not differ by CD4 level or by the use of HAART
at cancer diagnosis.
3.2 | Correlations between biomarker
expression, human immunodeficiency virus
infection and prognostic factors
As the study groups were not matched based on race, there
was a significantly greater proportion of African Americans
(46.3%) in the HIV-infected group than in the HIV-negative
group (6.8%; P < .001). The patients with HIV-positive
head and neck cancer (N 5 41) were about 4.5 years
younger than the patients with HIV-negative head and neck
cancer (N 5 44; P 5 .04) and were more frequently current
alcohol users (66% vs 23%; P < .001; Table 1). There was
no significant difference in sex, tumor stage, disease site,
HPV status, or smoking history between the HIV-positive
head and neck cancer and HIV-negative head and neck
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TABLE 1 Characteristics of patients with head and neck cancer by human immunodeficiency virus status
Covariate All patients (N 5 85) HIV-positive (N 5 41) HIV-negative (N 5 44) P value
Age, years, mean (6 SD) 51.9 (6 10.2) 49.6 (6 9.9) 54.1 (6 10.1) .04
Sex .67
Female 5 (5.9) 3 (7.3) 2 (4.6)
Male 80 (94.1) 38 (92.7) 42 (95.4)
Race < .001
African American 22 (25.9) 19 (46.3) 3 (6.8)
White 42 (49.4) 18 (43.9) 24 (54.5)
Unknown 21 (24.7) 4 (9.7) 17 (38.6)
Stage .36
I-II 23 (27.0) 14 (34.1) 9 (20.5)
III-IV 31 (36.5) 15 (36.6) 16 (36.4)
Unknown 31 (36.5) 12 (29.3) 19 (43.1)
Anatomic site
Larynx 45 (52.9) 21 (51.2) 24 (54.5)
Oral cavity 23 (27.1) 12 (29.3) 11 (25)
Oropharynx 3 (3.5) 1 (2.4) 2 (4.6)
Othera 14 (16.5) 7 (17.1) 7 (15.9) .98
HPV .60
Negative 61 (71.8) 26 (63.4) 35 (79.5)
Positive 16 (18.8) 8 (19.5) 8 (18.2)
Test invalid 8 (9.4) 7 (17.1) 1 (2.3)
CD4 at cancer diagnosisb (cells/lL) NA
<200 - 8 (19.5) -
200 - 24 (58.5) -
Unknown - 9 (22.0) -
HAART at cancer diagnosisc NA
No - 9 (21.9) -
Yes - 27 (65.9) -
Unknown - 5 (12.2) -
Alcohol history < .001
Current 37 (43.5) 27 (65.9) 10 (22.7)
Former 6 (7.1) 6 (14.6) 0 (0.0)
Never 16 (18.8) 3 (7.3) 13 (29.5)
Unknown 26 (30.6) 5 (12.2) 21 (47.7)
Smoking history .54
Current 42 (49.4) 29 (70.7) 13 (29.5)
Former 13 (15.3) 6 (14.6) 7 (15.9)
Never 2 (2.3) 2 (4.9) 0 (0.0)
Unknown 28 (32.9) 4 (9.8) 24 (54.5)
Abbreviations: CD4, Clavien-Dindo classification IV; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; HPV, human papillomavi-
rus; NA, not available.
Data are presented as number of patients (column %), mean (6 SD), or median (range).
P value is calculated by Student’s t test for numerical covariate, and chi-square or Fisher’s exact test for categorical variables as appropriate.
aOther anatomic site: 1 case of parotid gland cancer in the HIV-positive head and neck cancer group; and 1 case of esophageal cancer and 1 case of conjunctiva in
the HIV-negative head and neck cancer group.
bCD4 counts at the time of cancer diagnosis were identified for the HIV-positive head and neck cancer group only.
cHAART at the time of cancer diagnosis were identified for the HIV-positive head and neck cancer group only.
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cancer groups (Table 1). There was no significant difference
in the expression of each of the 7 biomarkers (pAKT, NF-
jB, pSTAT3, Bcl-2, TGF-b, IL-6, and VEGF) between the
HIV-positive head and neck cancer and the HIV-negative
head and neck cancer groups (Supporting Information Table
S2). After stratifying by disease stage, VEGF expression lev-
els were significantly lower in HIV-positive than HIV-
negative stages I-II head and neck cancer (P 5 .01). The
pSTAT3 expression levels were significantly lower in HIV-
positive than HIV-negative stages III-IV disease (P 5.03;
Table 2).
We also examined the expression of biomarkers by HPV
status. Levels of VEGF, IL-6, and NF-jB expression were
significantly lower in HPV-positive head and neck cancer
group than in the HPV-negative head and neck cancer group
(P < .001, P 5 .04, and P 5 .01, respectively; Figure 1A).
The other 4 biomarkers (pAKT, pSTAT3, Bcl-2, and TGF-
b) were not associated with HPV status. The pAKT, NF-jB,
and VEGF were expressed differentially by disease sites,
with highest expression in the oral cavity (Table 3; P <
.001, P < .001, and P 5 .02, respectively). Current alcohol
use was strongly associated with HIV-positive status com-
pared to former/never use (P < .001; Table 1), there was no
interaction effect on the expression of any biomarker among
HIV, HPV status, and alcohol use. Expression of pAKT was
significantly lower in current alcohol users than in former or
never users (Table 4; P 5 .02). White patients had higher
pAKT expression than African American patients (P 5 .01;
Table 4). The level of NF-jB was marginally significantly
lower in African American than in white patients (P 5 .06).
3.3 | Correlations among biomarkers
To verify the signals detected by TMA, we examined the
expression of key target molecules shared by the NF-jB and
pSTAT3 pathways, including VEGF, IL-6, pAKT, and Bcl-
2.17 In both groups, marked associations were observed of
pAKT with NF-jB (Supporting Information Table S3; P <
.001 in both HIV-positive and HIV-negative head and neck
cancer), NF-jB with VEGF (P 5 .02 in HIV-positive head
TABLE 2 Biomarker expression among patients with head and neck cancer stratified by human immunodeficiency virus status and stage
Stage and biomarker
HIV-positive head and neck cancer
N 5 29 (70.7% of total)
HIV-negative head and neck cancer
N 5 25 (56.9% of total) P valuea
I-II
p16-positive 7 (50%) 2 (22.2%) .23b
p16-negative 7 (50%) 7 (77.8%) .32
Bcl-2 8 (2-12) 7 (1-16)
pAKT 8.14 (3-16) 10.38 (1-16) .82
NF-jB 6 (3.2-8) 10 (1-14) .10
pSTAT3 6 (1-8.75) 2.63 (1-6) .11
TGF-b 5 (4-8) 7 (3-14) .36
VEGF 4 (2-8) 10 (6-12) .01
IL-6 7 (4-16) 9 (6-12.5) .70
III-IV
p16-positive 4 (26.7%) 6 (37.5%)
p16-negative 11 (73.3%) 10 (62.5%) .70
Bcl-2 6 (1.5-12) 8 (1-12) .66
pAKT 6 (1-14) 8 (2.3-16) .15
NF-jB 7 (1-10) 8 (1.7-12) .82
pSTAT3 1.15 (1-5.2)c 5 (1-7.59) .03
TGF-b 8 (2-12) 6 (1.5-16) .43
VEGF 8 (4.6-12) 8 (1-10) .17
IL-6 10.4 (7.5-12) 10.5 (2-16) .66
Abbreviations: Bcl-2, B-cell lymphoma 2; HIV, human immunodeficiency virus; IL-6, interleukin; NF-jB, nuclear factor-kappa b; pAKT, phosphorylated protein
kinase B; pSTAT3, phosphorylated signal transducer and activator of transcription 3; TGF-b, transforming growth factor-beta; VEGF, vascular endothelial growth
factor.
Data are presented as number of patients (column %) or median (range).
aThe P values are calculated by Wilcoxon rank-sum test or chi-square test.
bThe percentage of p16-positive or p16-negative cases over total number of cases with both p16 staining and stage information available was compared between
groups.
cThe level of pSTAT3 expression is significantly different by stage in the HIV-positive head and neck cancer group (P 5 .02).
No significant differences were detected by stage in the HIV-negative head and neck cancer group.
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and neck cancer; P < .001 in HIV-negative head and neck
cancer), and TGF-b with IL-6 (P 5 .006 in HIV-positive
head and neck cancer; P < .001 in HIV-negative head and
neck cancer), whereas an inverse correlation of pSTAT3
with TGF-b was observed only in the HIV-positive head and
neck cancer group (P < .05), and a correlation of Bcl-2 with
pAKT, NF-jB, and TGF-b was observed only in the HIV-
negative head and neck cancer group. When pAKT,
pSTAT3, and NF-jB were grouped as an oncogenic signa-
ture using combined score, univariate association revealed
that this signature was significantly associated with disease
site (P < .001), former and current alcohol use (P 5 .04),
and race (P 5 .02), but not with HIV status, HPV status, p16
positivity, age, sex, smoking history, CD4 count, or HAART
use at cancer diagnosis (data not shown). Using a combined
score of IL-6, VEGF, and TGF-b as a tumor microenviron-
ment signature, this score was significantly lower in the
HPV-positive group than in the HPV-negative group (P 5
.01).
3.4 | Prognostic value of biomarkers in
overall survival
Survival data was available for 37 of 41 HIV-positive head
and neck cancer cases (61.7%) and 23 of 44 HIV-negative
head and neck cancer controls (38.3%). Median follow-up







(N 5 14) P value
Bcl-2 8 (1-12) 6 (1-16) 6.5 (3.2-12) .41
pAKT 12 (1-16) 4.5 (1-16) 7.5 (1-14.4) < .001
NF-jB 8 (4.16-16) 6 (1-12) 5.49 (1.69-9.2) < .001
pSTAT3 3 (1-8) 2.17 (1-12) 2.1 (1-7.59) .94
TGF-b 6.95 (1-16) 4 (1.5-12) 6.6 (2-8) .13
VEGF 8 (1-14) 6 (2-12) 6.13 (2-10.5) .02
IL-6 10.4 (2-16) 9 (4-12) 10.15 (6.9-12.25) .55
Abbreviations: Bcl-2, B-cell lymphoma 2; IL-6, interleukin; NF-jB, nuclear factor-kappa b; pAKT, phosphorylated protein kinase B; pSTAT3, phosphorylated sig-
nal transducer and activator of transcription 3; TGF-b, transforming growth factor-beta; VEGF, vascular endothelial growth factor.
Data are presented as median (range).
P value is calculated by Wilcoxon rank-sum test.
aThese cases were not included in the analysis due to different histology origin: 1 case of parotid gland in the HIV-positive head and neck cancer group; 1 case of
esophageal and 1 case of conjunctiva in the HIV-negative head and neck cancer group.
FIGURE 1 A, Expression of 7 biomarkers by human papillomavirus (HPV) status presented as a boxplot. Expression levels of interleukin (IL)-6,
nuclear factor-kappab (NFjB), and vascular endothelial growth factor (VEGF) were significantly lower in the HPV-positive group than in the HPV-
negative group. B, Kaplan-Meier estimates for all patient cohorts by human immunodeficiency virus (HIV) status. Overall survival did not differ among
the patients in the HIV-positive head and neck cancer group and the HIV-negative head and neck cancer group. Bcl-2, B-cell lymphoma 2; pAKT, phos-
phorylated protein kinase B; pSTAT, phosphorylated signal transducer and activator of transcription; TGFb, transforming growth factor-beta
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was 565 days for the HIV-positive head and neck cancer
cases and 1095 days for the HIV-negative head and neck
cancer controls. Survival analysis was conducted for all
groups in which both biomarker and survival information
were available. When only the HIV-positive head and neck
cancer cases with all clinical covariables were considered,
univariate analysis showed that laryngeal disease site (P
5.003) and CD4 count <200 cells/lL (P 5 .01) were asso-
ciated with poor prognosis of overall survival (OS), whereas
HPV coinfection did not have a significant impact on OS
(Supporting Information Table S4). As expected, the HIV-
negative head and neck cancer group exhibited typically
poor prognosis associated with advanced age and stage (Sup-
porting Information Table S5). Multivariate analysis with all
biomarkers and clinical covariables in all patient groups is
summarized in Table 5. The best predictive survival model
using a Cox proportional hazard model included HIV infec-
tion, p16, pAKT, IL-6, and TGF-b. In the best predictive
model, HIV infection and p16 were treated as binary varia-
bles, whereas pAKT, IL-6, and TGF-b were treated as con-
tinuous variables. The HIV status did not have a significant
impact on OS in all patient groups after adjusting for the sig-
nificant biomarkers in the best predictive model (Figure 1B).
Improved OS was associated with positive p16 (P < .001)
TABLE 5 Multivariate overall survival analysis with biomarkers and covariates
Cohort Variables
HR
(95% CI) P value
HIV-positive head and neck cancer pAKT 0.73 (0.53-1.01) .05
IL-6 0.58 (0.29-1.14) .11
TGF-b 1.68 (0.94-2.99) .08
All patients HIV (positive vs negative) 1.78 (0.61-5.17) .29
p16 (positive vs negative) 0.12 (0.04-0.43) < .001
pAKT 0.80 (0.70-0.92) .002
IL-6 0.74 (0.60-0.92) .005
TGF-b 1.49 (1.17-1.89) .001
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; IL-6, interleukin; pAKT, phosphorylated protein kinase B; TGF-b,
transforming growth factor-beta.
Note: Survival data were available for 37 of 41 HIV-positive head and neck cancer cases and 23 of 44 HIV-negative head and neck cancer controls.










(N 5 42) P value
Bcl-2 6 (1-14.4) 8 (3.2-16) .13 6.5 (1.5-12) 7.25 (2-16) .65
pAKT 6.58 (1-16) 10.44 (1-16) .02 6 (1-12) 8 (1-16) .01
NF-jB 7 (1-14) 8 (2-16) .02 5.98 (1-10.5) 8 (1-16) .06
pSTAT3 3.84 (1-12) 5 (1-7.59) .59 3.6 (1-12) 3.68 (1-6) .60
TGF-b 6 (1-16) 7.6 (2-14) .16 5.5 (1-12) 6.9 (2-16) .24
VEGF 7.5 (2-12) 8 (1-14) .07 6.6 (2-12) 8 (1-14) .51
IL-6 9.9 (4-16) 10.25 (2-12.25) .57 9.45 (4-12.25) 10.4 (4-16) .27
Abbreviations: Bcl-2, B-cell lymphoma 2; IL-6, interleukin; NF-jB, nuclear factor-kappa b; pAKT, phosphorylated protein kinase B; pSTAT3, phosphorylated
signal transducer and activator of transcription 3; TGF-b, transforming growth factor-beta; VEGF, vascular endothelial growth factor.
Data are presented as median (range).
aUnknown cases of alcohol consumption were excluded from the analysis.
bUnknown cases of race were excluded from the analysis.
P values are calculated by Wilcoxon rank-sum test.
Note: Due to the small sample size, never drinkers were combined with former drinkers.
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and increased expression of pAKT (hazard ratio [HR] 0.80;
95% confidence interval [CI] 0.60-0.92; P 5 .002) and IL-6
(HR 0.74; 95% CI 0.60-0.92; P 5 .005), whereas increased
expression of TGF-b was associated with poor clinical out-
come (HR 1.49; 95% CI 1.17-1.89; P 5 .001).
4 | DISCUSSION
To our knowledge this is the first multi-institutional study
exploring the prognostic significance of a panel of tumor
biomarkers among patients with HIV-positive head and
neck cancer and HIV-negative head and neck cancer. To
reduce bias, comparison between groups was conducted by
pairing each tumor specimen based on anatomic site and
patient’s age whenever possible. We chose a panel of onco-
genic (NF-jB, pAKT, pSTAT3, and Bcl-2) and inflamma-
tory (TGF-b, IL-6, and VEGF) tumor biomarkers known to
play roles independently or cooperatively in tumor growth
and progression and tumor-host immune interaction.17–21
The subset of patients with HIV-positive head and neck
cancer largely retained the characteristics of the original
patient cohort, particularly, consistent with the findings in
the original study,15 we found that low CD4 count (<200
cells/lL) was significantly associated with poor OS in the
HIV-positive head and neck cancer cases when only clini-
cal information was included (Supporting Information Table
S4).34 In addition, current alcohol users were more likely to
have HIV infection compared with nonalcohol or former
alcohol users (OR 6.0; 95% CI 1.8-20.0; P 5 .003), con-
sistent with the high prevalence of lifestyle-related cancer
risk factors (smoking and alcohol intake) associated non-
AIDS-defining malignancies among patients with HIV
infection.7,35,36 The cases of HIV infection did not have
significant impact on patients’ OS, consistent with the find-
ings of investigators who used specimens derived from sim-
ilar cohorts.34
Our study has revealed that TGF-b expression stands out
as an independent poor prognosis factor for OS, a better
prognostic factor than stage, disease site, HIV, and/or HPV
infection when controlling for all clinical covariables and the
expression levels of the other biomarkers in all patient
groups (Table 2). The TGF-b, an inflammatory cytokine and
potent immune suppressor, plays a dual role in cancer devel-
opment by acting as a tumor suppressor during the early
stages and as a tumor promoter during the later stages of dis-
ease.20 One of the mechanisms by which tumor TGF-b may
promote tumorigenesis is through acting as a potent immuno-
suppressor, and/or recruiting regulatory T cells (CD25 6
Foxp3) and myeloid-derived suppressor cells,19 thus decreas-
ing tumor cell recognition and clearing by the innate immune
system. In a recent randomized phase II trial of cetuximab
with or without sorafenib in recurrent and/or metastatic
SCCHN, high plasma TGF-b was found to be associated
with inferior progression-free survival regardless of the study
arm.37 Furthermore, patients with SCCHN receiving single-
agent cetuximab had increased frequency of CD41FOXP31
intratumoral recruiting regulatory T cells expressing CTLA-
4, CD39, and TGF-b, which were associated with sup-
pressed cetuximab-mediated antibody-dependent cellular
cytotoxicity and poor clinical outcomes.38 These studies
underscore the complexity of proinflammatory tumor
markers and demand more systematic future approaches to
study tumor biomarkers, including host immune status,
tumor infiltrating cells, and genomic approaches to identify
molecular signatures with prognostic value. In addition to
TGF-b being detected as a significant negative prognostic
factor, multivariate analysis detected a statistically significant
effect of p16 positivity and increased pAKT and IL-6 expres-
sion on OS. The strong prognostic effect of positive p16 on
superior clinical outcome was detected in all patient groups,
including oral cavity, laryngeal, and oropharyngeal disease
site. Our findings are consistent with those of a study assess-
ing the prognostic effect of positive p16 by IHC in oral cav-
ity, hypopharyngeal, and laryngeal cancers.39 It has been
reported that elevated systemic IL-6 level at baseline was
strongly related with all-cause mortality in patients infected
with HIV40 and at 1 year post-HAART treatment with non-
AIDS-defining events.41 It remains to be examined whether
the levels of host systemic IL-6 and tumor IL-6 convey simi-
lar or different profiles regarding host immune status. The
slightly beneficial effect of both pAKT and IL-6 expression
on OS indicated by the odd ratios (Table 5) warrants further
investigation.
Evidence of a differential effect of HPV on tumor bio-
markers in SCCHN has begun to emerge.42 The current
study observed lower expression levels of IL-6, VEGF, and
NF-jB in the HPV-positive head and neck cancer group
than in the HPV-negative head and neck cancer group (Fig-
ure 1A), furthermore, the strong association of VEGF with
NF-jB was not affected by HIV infection (Supporting Infor-
mation Table S3). A recent biomarker study of head and
neck cancer tissues from the base of tongue, tonsils, and
vocal fold revealed that tumor IL-6 assessed by IHC and
serum IL-6 were significantly lower in patients with HPV16-
positive disease (N 5 11) than in HPV-negative patients (N
5 11), but IL-6 expression levels were not correlated with
SCCHN location, stage, or level of HPV viral load.43 A
study of hypoxia-related genes in oropharyngeal squamous
cell carcinoma found that HPV-positive tumors displayed
less hypoxia than HPV-negative tumors.44 A study using
high-throughput analyses and the TRANScription FACtor
(TRANSFAC) database reported that HPV-positive tumors
had reduced whole cell protein expression and significantly
lower nuclear staining of both STAT3 and NF-jB by IHC
than HPV-negative tumors, marked colocalization, and
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coactivation of both transcription factors was observed by
TMA.45 Taken together, our findings are consistent with the
consensus that HPV infection has significant effects on the
tumor expression of IL-6, VEGF, and NF-jB.
We were surprised by a more prominent effect of disease
anatomic site (Table 3), race, and alcohol use (Table 4) than
HIV infection and CD4 counts on biomarker expression. This
is consistent with the notion of distinct molecular signatures
according to disease anatomic site and the impact of risk
behaviors, such as cigarette smoking on tumor genetic charac-
teristics identified by the Cancer Genome Atlas investiga-
tions.28 The lack of significant effect of HIV infection raises
further questions, such as whether a patient’s viral load may
be a better prognostic factor than HIV infection for disease
progression and OS, whether HIV infection alone or HPV
coinfection may have significant effect on tumor biomarker
expression, and whether the anatomic site and/or risk behav-
iors may have greater impact than HIV infection on tumor
molecular characteristics and behaviors. Whether these factors
are related to the strong association of the prevalence of HIV-
positive head and neck cancer with race, sex, age, CD4 counts,
and risk behaviors1,2,12 certainly warrants further investigation.
The limitations of this study include the retrospective
and observational nature of the design, limited sample size,
missing information of stage and viral load, single patholo-
gist review, and the lack of information on detailed treatment
history and progression-free survival, which is highly rele-
vant to disease progression.
In summary, tumor biomarkers were not differentially regu-
lated by HIV status and HIV infection did not have significant
impact on OS of patients with head and neck cancer. The high
expression of TGF-b was significantly associated with poor
OS, whereas positive p16 status was significantly associated
with improved OS. Addition of biomarkers, such as TGF-b, to
the conventional risk stratification equation could improve prog-
nostic and predictive values, and it would be desirable to imple-
ment a disease management strategy targeting this growing but
largely underinvestigated patient population.
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